Franco Valle
Financieel Directeur/CFO bij BIOMEA FUSION, INC.
Vermogen: 268 712 $ op 31-05-2024
Actieve functies van Franco Valle
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BIOMEA FUSION, INC. | Comptroller/Controller/Auditor | 26-07-2021 | - |
| Financieel Directeur/CFO | 26-07-2021 | - |
Loopbaan van Franco Valle
Eerdere bekende functies van Franco Valle
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| EIDOS THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01-01-2020 | 01-04-2021 |
| Financieel Directeur/CFO | 01-01-2020 | 01-04-2021 | |
| Corporate Officer/Principal | 01-03-2018 | 01-01-2020 | |
| IOVANCE BIOTHERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01-07-2016 | 01-01-2018 |
| Financieel Directeur/CFO | 26-07-2017 | 14-08-2017 | |
Pharmacyclics, Inc.
 Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Comptroller/Controller/Auditor | 01-01-2012 | 01-05-2015 |
| PHARMACYCLICS, INC. | Comptroller/Controller/Auditor | - | - |
| LENZ THERAPEUTICS, INC. | Financieel Directeur/CFO | - | - |
Opleiding van Franco Valle
| San Jose State University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 8 |
Operationeel
| Comptroller/Controller/Auditor | 5 |
| Director of Finance/CFO | 4 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 7 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| BIOMEA FUSION, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Pharmacyclics, Inc.
Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Health Technology |
- Beurs
- Insiders
- Franco Valle
- Ervaring
